Alprazolam

Alprazolam is a short-acting, high-potency triazolobenzodiazepine. It enhances the binding affinity of the major inhibitory neurotransmitter GABA to GABAA receptors, opening neuronal chloride ion channels, hyperpolarizing membranes, and producing rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. Indicated for acute management of generalized anxiety disorder (GAD) and panic disorder with or without agoraphobia.

Alprazolam is a short-acting, high-potency triazolobenzodiazepine. It enhances the binding affinity of the major inhibitory neurotransmitter GABA to GABAA receptors, opening neuronal chloride ion channels, hyperpolarizing membranes, and producing rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. Indicated for acute management of generalized anxiety disorder (GAD) and panic disorder with or without agoraphobia.

Alprazolam and Fluoxetine combines a fast-acting triazolobenzodiazepine with a selective serotonin reuptake inhibitor (SSRI). Alprazolam rapidly relieves acute psychic anxiety, insomnia, and agitation within hours, while fluoxetine provides sustained long-term modulation of central serotonergic pathways to treat underlying depressive and panic pathology over weeks. Indicated for major depressive disorder with comorbid anxiety or agitation.

Alprazolam and Propranolol Hydrochloride is a synergistic psychotropic-cardiovascular formulation combining a triazolobenzodiazepine with a non-selective beta-adrenergic blocker. Alprazolam enhances central inhibitory GABAergic neurotransmission at the GABAA receptor, relieving psychological panic and tension, while propranolol competitively antagonizes peripheral beta-1 and beta-2 adrenergic receptors, curbing somatic autonomic manifestations of anxiety (palpitations, resting tachycardia, tremors, sweating). Indicated for situational anxiety, panic disorder with severe autonomic hyperactivity, and performance anxiety.

Alprazolam and Propranolol Hydrochloride is a synergistic psychotropic-cardiovascular formulation combining a triazolobenzodiazepine with a non-selective beta-adrenergic blocker. Alprazolam enhances central inhibitory GABAergic neurotransmission at the GABAA receptor, relieving psychological panic and tension, while propranolol competitively antagonizes peripheral beta-1 and beta-2 adrenergic receptors, curbing somatic autonomic manifestations of anxiety (palpitations, resting tachycardia, tremors, sweating). Indicated for situational anxiety, panic disorder with severe autonomic hyperactivity, and performance anxiety.

Alprazolam and Sertraline pairs an immediate-acting high-potency benzodiazepine with an SSRI. Alprazolam bridges the initial 2-4 week lag phase of antidepressant therapy by rapidly controlling severe anxiety, panicky distress, and insomnia, while sertraline elevates synaptic serotonin to alleviate core depressive illness. Indicated for major depressive episodes accompanied by prominent anxiety symptoms.

Alprazolam and Sertraline pairs an immediate-acting high-potency benzodiazepine with an SSRI. Alprazolam bridges the initial 2-4 week lag phase of antidepressant therapy by rapidly controlling severe anxiety, panicky distress, and insomnia, while sertraline elevates synaptic serotonin to alleviate core depressive illness. Indicated for major depressive episodes accompanied by prominent anxiety symptoms.